Allogeneic-blood stem-cell collection following mobilization with low- dose granulocyte colony-stimulating factor

Michael R. Bishop, Stefano R. Tarantolo, John D. Jackson, James R. Anderson, Kim Schmit-Pokorny, Diane Zacharias, Zivko S. Pavletic, Samuel Jay Pirruccello, Julie Marie Vose, Philip Jay Bierman, Phyllis Irene Warkentin, James Olen Armitage, Anne Kessinger

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose: The optimal dose of granulocyte colony-stimulating factor (G- CSF) for mobilizatlon of allogeneic-blood stem cells (AlloBSC) has yet to be determined. As part of a prospective trial, 41 related human leukocyte antigen (HLA)-matched donors had blood cells mobilized with G-CSF at 5 μg/kg/d by subcutaneous administration. The purpose of this trial was to monitor adverse effects during G-CSF administration and stem-cell collection, to determine the optimal timing for stem-cell collection, and to determine the cellular composition of stem-cell products following G-CSF administration. Patients and Methods: The median donor age was 42 years. Apheresis began an day 4 of G-CSF administration. At least three daily 12-L apheresis collections were performed on each donor. A minimum of 1.0 x 106 CD34+ cells/kg (recipient weight) and 8.0 x 108 mononuclear cells/kg were collected from each donor. All collections were cryopreserved in 5% dimethyl sulfoxide and 6% hydroxyethyl starch. Results: Toxicities associated with G- CSF administration and the apheresis process included myalgias/arthralgias (83%), headache (44%), fever (27%), and chills (22%). The median baseline platelet count of 242 x 106/mL decreased to 221, 155, and 119 x 106/mL on days 4, 5, and 6 of G-CSF administration, respectively. Median numbers of CD34+ cells in collections 1, 2, and 3 were 1.99, 2.52, and 3.13 x 106/kg, respectively. The percentage and total number of CD4+, CD8+, and CD56+/CD3- cells remained relatively/constant during the three collections. Median total numbers of cells were as follows: CD34+, 7.73 x 106/kg; and lymphocytes, 6.93 x 108/kg. Conclusion: Relatively low doses of G-CSF can mobilize sufficient numbers of AlloBSC safely and efficiently.

Original languageEnglish (US)
Pages (from-to)1601-1607
Number of pages7
JournalJournal of Clinical Oncology
Volume15
Issue number4
DOIs
StatePublished - Apr 1997

Fingerprint

Granulocyte Colony-Stimulating Factor
Blood Cells
Stem Cells
Blood Component Removal
Tissue Donors
Cell Count
Chills
Myalgia
Arthralgia
HLA Antigens
Dimethyl Sulfoxide
Platelet Count
Starch
Headache
Fever
Lymphocytes
Weights and Measures

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Bishop, M. R., Tarantolo, S. R., Jackson, J. D., Anderson, J. R., Schmit-Pokorny, K., Zacharias, D., ... Kessinger, A. (1997). Allogeneic-blood stem-cell collection following mobilization with low- dose granulocyte colony-stimulating factor. Journal of Clinical Oncology, 15(4), 1601-1607. https://doi.org/10.1200/JCO.1997.15.4.1601

Allogeneic-blood stem-cell collection following mobilization with low- dose granulocyte colony-stimulating factor. / Bishop, Michael R.; Tarantolo, Stefano R.; Jackson, John D.; Anderson, James R.; Schmit-Pokorny, Kim; Zacharias, Diane; Pavletic, Zivko S.; Pirruccello, Samuel Jay; Vose, Julie Marie; Bierman, Philip Jay; Warkentin, Phyllis Irene; Armitage, James Olen; Kessinger, Anne.

In: Journal of Clinical Oncology, Vol. 15, No. 4, 04.1997, p. 1601-1607.

Research output: Contribution to journalArticle

Bishop, Michael R. ; Tarantolo, Stefano R. ; Jackson, John D. ; Anderson, James R. ; Schmit-Pokorny, Kim ; Zacharias, Diane ; Pavletic, Zivko S. ; Pirruccello, Samuel Jay ; Vose, Julie Marie ; Bierman, Philip Jay ; Warkentin, Phyllis Irene ; Armitage, James Olen ; Kessinger, Anne. / Allogeneic-blood stem-cell collection following mobilization with low- dose granulocyte colony-stimulating factor. In: Journal of Clinical Oncology. 1997 ; Vol. 15, No. 4. pp. 1601-1607.
@article{e6007b4f1d0444b1933115ac0943b241,
title = "Allogeneic-blood stem-cell collection following mobilization with low- dose granulocyte colony-stimulating factor",
abstract = "Purpose: The optimal dose of granulocyte colony-stimulating factor (G- CSF) for mobilizatlon of allogeneic-blood stem cells (AlloBSC) has yet to be determined. As part of a prospective trial, 41 related human leukocyte antigen (HLA)-matched donors had blood cells mobilized with G-CSF at 5 μg/kg/d by subcutaneous administration. The purpose of this trial was to monitor adverse effects during G-CSF administration and stem-cell collection, to determine the optimal timing for stem-cell collection, and to determine the cellular composition of stem-cell products following G-CSF administration. Patients and Methods: The median donor age was 42 years. Apheresis began an day 4 of G-CSF administration. At least three daily 12-L apheresis collections were performed on each donor. A minimum of 1.0 x 106 CD34+ cells/kg (recipient weight) and 8.0 x 108 mononuclear cells/kg were collected from each donor. All collections were cryopreserved in 5{\%} dimethyl sulfoxide and 6{\%} hydroxyethyl starch. Results: Toxicities associated with G- CSF administration and the apheresis process included myalgias/arthralgias (83{\%}), headache (44{\%}), fever (27{\%}), and chills (22{\%}). The median baseline platelet count of 242 x 106/mL decreased to 221, 155, and 119 x 106/mL on days 4, 5, and 6 of G-CSF administration, respectively. Median numbers of CD34+ cells in collections 1, 2, and 3 were 1.99, 2.52, and 3.13 x 106/kg, respectively. The percentage and total number of CD4+, CD8+, and CD56+/CD3- cells remained relatively/constant during the three collections. Median total numbers of cells were as follows: CD34+, 7.73 x 106/kg; and lymphocytes, 6.93 x 108/kg. Conclusion: Relatively low doses of G-CSF can mobilize sufficient numbers of AlloBSC safely and efficiently.",
author = "Bishop, {Michael R.} and Tarantolo, {Stefano R.} and Jackson, {John D.} and Anderson, {James R.} and Kim Schmit-Pokorny and Diane Zacharias and Pavletic, {Zivko S.} and Pirruccello, {Samuel Jay} and Vose, {Julie Marie} and Bierman, {Philip Jay} and Warkentin, {Phyllis Irene} and Armitage, {James Olen} and Anne Kessinger",
year = "1997",
month = "4",
doi = "10.1200/JCO.1997.15.4.1601",
language = "English (US)",
volume = "15",
pages = "1601--1607",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Allogeneic-blood stem-cell collection following mobilization with low- dose granulocyte colony-stimulating factor

AU - Bishop, Michael R.

AU - Tarantolo, Stefano R.

AU - Jackson, John D.

AU - Anderson, James R.

AU - Schmit-Pokorny, Kim

AU - Zacharias, Diane

AU - Pavletic, Zivko S.

AU - Pirruccello, Samuel Jay

AU - Vose, Julie Marie

AU - Bierman, Philip Jay

AU - Warkentin, Phyllis Irene

AU - Armitage, James Olen

AU - Kessinger, Anne

PY - 1997/4

Y1 - 1997/4

N2 - Purpose: The optimal dose of granulocyte colony-stimulating factor (G- CSF) for mobilizatlon of allogeneic-blood stem cells (AlloBSC) has yet to be determined. As part of a prospective trial, 41 related human leukocyte antigen (HLA)-matched donors had blood cells mobilized with G-CSF at 5 μg/kg/d by subcutaneous administration. The purpose of this trial was to monitor adverse effects during G-CSF administration and stem-cell collection, to determine the optimal timing for stem-cell collection, and to determine the cellular composition of stem-cell products following G-CSF administration. Patients and Methods: The median donor age was 42 years. Apheresis began an day 4 of G-CSF administration. At least three daily 12-L apheresis collections were performed on each donor. A minimum of 1.0 x 106 CD34+ cells/kg (recipient weight) and 8.0 x 108 mononuclear cells/kg were collected from each donor. All collections were cryopreserved in 5% dimethyl sulfoxide and 6% hydroxyethyl starch. Results: Toxicities associated with G- CSF administration and the apheresis process included myalgias/arthralgias (83%), headache (44%), fever (27%), and chills (22%). The median baseline platelet count of 242 x 106/mL decreased to 221, 155, and 119 x 106/mL on days 4, 5, and 6 of G-CSF administration, respectively. Median numbers of CD34+ cells in collections 1, 2, and 3 were 1.99, 2.52, and 3.13 x 106/kg, respectively. The percentage and total number of CD4+, CD8+, and CD56+/CD3- cells remained relatively/constant during the three collections. Median total numbers of cells were as follows: CD34+, 7.73 x 106/kg; and lymphocytes, 6.93 x 108/kg. Conclusion: Relatively low doses of G-CSF can mobilize sufficient numbers of AlloBSC safely and efficiently.

AB - Purpose: The optimal dose of granulocyte colony-stimulating factor (G- CSF) for mobilizatlon of allogeneic-blood stem cells (AlloBSC) has yet to be determined. As part of a prospective trial, 41 related human leukocyte antigen (HLA)-matched donors had blood cells mobilized with G-CSF at 5 μg/kg/d by subcutaneous administration. The purpose of this trial was to monitor adverse effects during G-CSF administration and stem-cell collection, to determine the optimal timing for stem-cell collection, and to determine the cellular composition of stem-cell products following G-CSF administration. Patients and Methods: The median donor age was 42 years. Apheresis began an day 4 of G-CSF administration. At least three daily 12-L apheresis collections were performed on each donor. A minimum of 1.0 x 106 CD34+ cells/kg (recipient weight) and 8.0 x 108 mononuclear cells/kg were collected from each donor. All collections were cryopreserved in 5% dimethyl sulfoxide and 6% hydroxyethyl starch. Results: Toxicities associated with G- CSF administration and the apheresis process included myalgias/arthralgias (83%), headache (44%), fever (27%), and chills (22%). The median baseline platelet count of 242 x 106/mL decreased to 221, 155, and 119 x 106/mL on days 4, 5, and 6 of G-CSF administration, respectively. Median numbers of CD34+ cells in collections 1, 2, and 3 were 1.99, 2.52, and 3.13 x 106/kg, respectively. The percentage and total number of CD4+, CD8+, and CD56+/CD3- cells remained relatively/constant during the three collections. Median total numbers of cells were as follows: CD34+, 7.73 x 106/kg; and lymphocytes, 6.93 x 108/kg. Conclusion: Relatively low doses of G-CSF can mobilize sufficient numbers of AlloBSC safely and efficiently.

UR - http://www.scopus.com/inward/record.url?scp=17744409297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744409297&partnerID=8YFLogxK

U2 - 10.1200/JCO.1997.15.4.1601

DO - 10.1200/JCO.1997.15.4.1601

M3 - Article

C2 - 9193359

AN - SCOPUS:17744409297

VL - 15

SP - 1601

EP - 1607

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -